We have investigated the effects of recombinant human erythropoietin (EPO) on the responses of rat renal arcuate arteries to dopamine, noradrenaline and acetylcholine and on the release of NO from human umbilical vein endothelial cells (HUVEC) in culture. Noradrenaline induced a concentration-dependent constriction and acetylcholine a concentration-dependent relaxation of the vessels. The effects of dopamine were concentration-dependent, leading to relaxation of the vessels at low concentrations and contraction of the vessels at high concentrations. N GNitro-L-arginine methyl ester (L-NAME ; 0.1 mM) did not change the vasoconstrictor responses to noradrenaline and dopamine, but inhibited the acetylcholine-and dopamine-induced vasorelaxation. Neither 0.1 nor 20 units:ml − 1 EPO affected noradrenaline-induced constriction, or dopamine-or acetylcholine-induced relaxation, of the vessels. EPO at 20 units:ml − 1 attenuated dopamine-induced constriction of the vessels. This effect was blunted by application of L-NAME, suggesting that EPO may stimulate dopamine-mediated NO release from these vessels. EPO stimulated NO release from the resting HUVEC in a concentration-and time-dependent manner, an effect that was inhibited by the presence of N G -nitro-L-arginine. These data suggest that, in vitro, EPO is able to stimulate NO release from rat renal arcuate arteries and HUVEC in culture. Whether these acute short-term actions can be related to the longer-term actions of EPO remains to be resolved.
INTRODUCTION
There is increasing interest in the interaction between erythropoietin (EPO) and nitric oxide (NO). It is recognized that hypoxia is one of the most important stimuli for EPO generation, and may also have the ability to promote the expression of inducible NO synthase [1] . It has also been suggested that EPO may stimulate NO release directly from endothelial cells. This may explain the fact that, whereas chronic EPO administration is associated with a rise in blood pressure and peripheral vascular resistance, it is not associated with an accelerated decline in renal function in patients with renal impairment. This is supported by the report of Tsukahara et al. [2] , who treated Sprague-Dawley rats with EPO three times per week for 2 weeks, inducing hypertension which was associated with increased urinary NO # − and NO $ − excretion. Co-administration of N G -nitro-L-arginine methyl ester (L-NAME ; a non-selective NO synthase inhibitor), but not of aminoguanidine (an inhibitor of inducible NO synthase) [3] , reduced NO # − and NO $ − excretion. This would suggest that EPO has a significant pressor effect and, in addition, induces a compensatory increase in the release of NO by constitutive NO synthase in normal rats. Furthermore, single-dose administration of EPO was found to cause an increase in plasma cGMP levels in rats [4] , and EPO therapy for 1.5 months led to an increase in plasma cGMP levels in haemodialysis patients [5] . This further suggests that EPO interacts with the NO\cGMP pathway in rats and in humans. However, whether the EPO-induced increases in urinary NO # − and NO $ − excretion and plasma cGMP levels were due to an increase in vascular wall shear stress consequent to raised blood pressure and\or increased blood viscosity (the major stimuli for NO release from the vascular wall), or to a direct effect of EPO itself on the vasculature, has not yet been determined.
It is difficult to interpret the role of NO in EPOinduced hypertension, since NO is considered to be an important vasodilator. Using telethermography, it has been demonstrated that the acetylcholine-induced relaxation of the dorsal pedal subcutaneous artery of normal humans was blunted by graded doses of EPO [6] , suggesting that EPO may impair the synthesis of endothelial NO in this vasculature. Moreover, EPO treatment (150 units:kg −" ; twice per week for 6 weeks) in rats raised the blood pressure and impaired the hypotensive response to sodium nitroprusside, a NO donor, but did not change caudal artery contraction in response to depolarization induced by 68 mM potassium [7] , suggesting that EPO-induced hypertension may be associated with an impaired vasodilatory response to NO.
The aim of the present study was to examine in greater detail the relationship between EPO and NO production. This was done, firstly, by examining the influence of EPO on vasodilator and vasoconstrictor responses of rat renal resistance vessels to a range of agonists, and determining how they are influenced following blockade of NO production with L-NAME ; and secondly by examining directly the ability of EPO to stimulate NO release from endothelial cells.
METHODS

Vascular studies
Preparation of vessels
Male Wistar rats (body weight 300-400 g) were killed by CO After an equilibration period of 1 h in PSS, the passive tension\internal circumference characteristics were determined [8] . The vessels were then set to an internal circumference equivalent to 90 % of that they would have when relaxed in situ under a transmural pressure of 100 mmHg. The maximum active tension is developed at approximately this circumference [8] . The vessels were then maximally contracted for 2 min every 10 min on four occasions. The first two contractions were with KPSS plus 5 µM noradrenaline, followed by 5 µM noradrenaline, and finally by KPSS. Any vessels that failed to develop a maximum tension equivalent to a pressure of 100 mmHg were discarded.
Experimental protocol
Cumulative concentration-response curves were constructed, using groups of 6-11 vessels, to acetylcholine (0.01-100 µM) (arteries pre-contracted with 5 µM noradrenaline), noradrenaline (0.01-10 µM) and dopamine [1 µM-0.7 mM (contractions) and 0.01-20 µM (relaxations) arteries pre-contracted with 0.2 µM U46619, a synthetic analogue of prostaglandin F # α ]. Each concentration of agonist was left in contact with the vessels for 2 min, with the tension being recorded at the end of the period. Following each concentrationresponse curve, the vessels were washed with PSS and rested in PSS for 10 min. The groups of vessels were then incubated with 0.1 or 20 units:ml −" EPO for 1 h, 0.1 mM L-NAME alone for 30 min, or a combination of L-NAME and 20 units:ml −" EPO. The concentrationresponse curves were then repeated with acetylcholine, noradrenaline or dopamine in the presence of the appropriate combination of agents. Each vessel was subjected to no more than three agonists.
The experimental protocol involved repeating concentration-response curves to acetylcholine, noradrenaline and dopamine on two occasions. In order to exclude changes in the sensitivity of the vessels with repeated exposure, timed controls were performed as follows. Concentration-response curves were obtained to acetylcholine, noradrenaline and dopamine as above ; the vessels were then washed in PSS and allowed to rest for 10 min, and the concentration-response curves were repeated.
Cell culture
Preparation of cells
Human umbilical vein endothelial cells (HUVEC) were isolated by a modification of the method originally described by Jaffe et al. [9] . The cell suspension was spun at 200 g for 3 min and resuspended in medium supplemented with 20 % (v\v) fetal calf serum, 10 000 units:ml −" penicillin, 10 000 mg:ml −" streptomycin, 0.03 mg:ml −" glutamine, 50 units:ml −" heparin and 0.1 mg:ml −" bovine brain extract. Cells were seeded into an 80 cm# tissue culture flask pre-coated with gelatin for 20 min and incubated at 37 mC in a 5% CO # humidified incubator. The medium was changed on the second day of culture and renewed twice weekly thereafter. Cells were passaged every 7 days. Cells were detached with 0.05 % (w\v) trypsin\0.02 % (w\v) EDTA. The suspension was re-seeded by adding 1 ml (2i10' cells) to 10 ml of medium in a pre-coated flask. Passages 3-4 were used.
NO measurement
Cells were seeded into 96-well plates at 2i10% cells:well −" . The plates were kept in an incubator at 37 mC, gassed with 95 % O # and 5 % CO
#.
After an overnight incubation, the medium was changed to complete medium containing various concentrations of EPO from 0 to 200 units:ml −". The same medium containing corresponding concentrations of EPO was added to wells without cells to act as background controls. Replicates of six wells were used for each concentration of EPO. The cells were incubated for 1, 8, 24 or 48 h at different concentrations of EPO, to examine the time-and concentration-dependence of NO production. N GNitro-L-arginine (L-NNA) was added to a group of wells with or without HUVEC, in the presence of EPO (20 units:ml −" ), and incubated for 8 h to investigate the effect of L-NNA on NO production. The supernatants were then collected and NO concentrations were measured [10] using a chemiluminescence analyser (Sievers 270B). At least three or four runs were performed for each experiment, using different sets of cells on each occasion.
Cell proliferation
In order to ensure that any changes in NO release from HUVEC were related to increased production per cell rather than to a proliferative effect of EPO leading to increased cell numbers, the effect of EPO on cell proliferation was examined under the same experimental conditions. Cell proliferation was measured using [$H]thymidine uptake and cell counting. HUVEC were seeded into 96-well plates at 2i10% cells:well −" . After overnight cell attachment, the medium was changed to complete medium containing [$H]thymidine (15 µCi:ml −" ) and various concentrations of EPO. After a 8 or 24 h incubation, the cells were collected on filtermats by a harvester (Skatron) and dried overnight at room temperature. The radioactivity of the filtermats was measured on a liquid scintillation counter (1205 Betaplate2 ; Pharmacia).
Chemicals
Acetylcholine, dopamine, U46619, L-NAME, L-NNA, noradrenaline, sodium iodide and acetic acid were purchased from Sigma (Poole, Dorset, U.K.). SNP was from David Bull Laboratories. EPO was from Janssen-Cilag. 199 medium, fetal calf serum, penicillin, streptomycin, glutamine and trypsin were purchased from Gibco (Paisley, Scotland, U.K.). Heparin was from CP Pharmaceuticals Ltd. (Wrexham, Wales, U.K.). Other reagents were purchased from BDH (Poole, Dorset, U.K.). All reagents were of AnalaR grade, and solutions were prepared fresh daily.
Statistics
Values of klogn(EC
; M) were calculated using a computerized curve-fitting software package (Graphpad Inplot, version 3.14). Where curve fitting was not appropriate, the maximum responses were compared. Relaxations in response to acetylcholine and dopamine are expressed as a percentage of the pre-contraction value in response to noradrenaline and U46619 respectively. Contractions in response to noradrenaline and dopamine are expressed as active tension (mN:mm −" ). All values are given as meanspS.E.M. Differences between means were assessed using Student's t-test for paired or unpaired data, as appropriate, and differences between curves were assessed using a one-way analysis of variance (ANOVA).
RESULTS
Effects of EPO on isolated rat renal arcuate arteries
Noradrenaline induced concentration-dependent contractions of the vessels, with a maximum response between 5 and 10 µM. Repetition of the concentrationresponse curve was not associated with a significant change in either the maximum response or the pEC &! value (Table 1) . L-NAME did not significantly affect the concentration-response curve to noradrenaline (Table 1) . Similarly, neither concentration of EPO used significantly affected the concentration-response relationship for noradrenaline (Table 1) .
Dopamine at concentrations between 1 µM and 0.7 mM induced concentration-dependent contractions of the vessels, with a maximum response at approx. 5 µM. Repetition of the concentration-response curve, as a time control, was not associated with a significant change in either the maximum response or the pEC &! (Table 2 ). L-NAME had no significant effect on the concentrationresponse curve to dopamine ( Figure 1a ; Table 2 ). Incubation with EPO at 20 units:ml −" , but not at 0.1 unit:ml −" , for 1 h (Table 2 ) attenuated the contractile response of the vessels to dopamine, shifting the curve to the right (P 0.001, ANOVA ; Figure 1b ) and decreasing the maximum tension developed (P 0.05) and the pEC &! value (P 0.01). The inhibitory effect of the high concentration of EPO was abolished in the presence of L-NAME ( Figure 1c ; Table 2 ).
Dopamine at concentrations between 0.01 and 20 µM induced a concentration-dependent relaxation of vessels pre-contracted with U46619, with a maximum relaxation of around 50 % at 10-20 µM dopamine. Repetition of the concentration-response curve was associated with potentiation of the relaxation obtained (Table 3) . However, further repetition was not associated with any significant potentiation. Thus concentration-response curves were performed on three occasions, with the results from the first curve being discarded and curves 2 and 3 being used for the experimental observations. L-NAME significantly attenuated the relaxation to dopamine by shifting the curve to the right (P 0.01, ANOVA) relative to its paired control and time control, although this effect was small, and neither the maximum relaxation obtained nor the pEC
&!
was changed significantly. Pre-incubation with EPO at 0.1 or 20 units:ml −" did not significantly alter the maximum response of the vessels to dopamine when compared with the relevant timed controls (Table 3) .
Acetylcholine induced a concentration-dependent relaxation of vessels pre-constricted with noradrenaline. The response was relatively small, with a maximum relaxation of approx. 25 % at 100 µM acetylcholine. Repetition of the concentration-response curve as a time control did not significantly alter the response obtained (Table 4) . Incubation of the vessels with L-NAME completely abolished the relaxation to acetylcholine (P 0.001), and a pEC &! could not be obtained (Table 4 ). The presence of EPO at either 0.1 or 20 units:ml −" had no significant effect on the acetylcholine-induced relaxation (Table 4) .
Effects of EPO on NO release from HUVEC
Incubation of HUVEC for 1 h with increasing concentrations of EPO resulted in a concentration-dependent release of NO, which became significant (P 0.05) at an EPO concentration of 200 units:ml −" (Figure 2a ). NO production following incubation with 20 units:ml −" EPO was significantly elevated at 8 h (P 0.01), peaked at 24 h (P 0.001), and had fallen at 48 h, although it remained significantly elevated (P 0.01) (Figure 2b) . Incubation of HUVEC with increasing concentrations of EPO for 8 h resulted in a concentration-dependent release of NO, which became significant at a concentration of 0.1 unit:ml −" EPO (P 0.05) and peaked at 40 units:ml −" (P 0.001) (Figure 2c ). Co-incubation of EPO (20 units:ml −" ) and L-NNA (0.1 mM) resulted in no significant increase in NO production when compared with baseline (Figure 2c ).
Effect of EPO on cell proliferation
Incubation of HUVEC with various concentrations of EPO for 8 or 24 h did not affect [$H]thymidine uptake by the cells (Table 5) .
DISCUSSION
The main findings from this study were that EPO, at high concentrations, attenuated the contractile response of rat renal arcuate arteries to dopamine, and that this effect was in turn attenuated by co-incubation with L-NAME, suggesting that EPO induced NO release from these vessels when contracted in response to the specific agonist dopamine. This conclusion was supported to some extent by the observation that EPO induced NO release from HUVEC in culture in a time-and concentrationdependent manner. Two concentrations of EPO were studied : 0.1 unit:ml −" , which approximately corresponds to values observed therapeutically, and 20 units:ml −" , which may approach concentrations found within the renal interstitium and the normal physiological environment of the renal arcuate arteries. It was considered that investigating contractile responses in the presence of both of these concentrations of EPO might provide useful information.
It is likely, given the high concentration used, that the dopamine-induced contraction was mediated, at least in part, via activation of α-adrenoceptors. Indeed, the magnitude and pattern of the contractions were similar to those obtained with noradrenaline. L-NAME did not alter the contractions induced by either dopamine or noradrenaline under these conditions. We have previously demonstrated that the effect of L-NAME on noradrenaline-induced contraction is only apparent in the presence of indomethacin [11] , and it is possible that this also applies to dopamine. Dopamine-induced contraction of the vessels was attenuated by co-incubation with a high concentration of EPO. This is probably one of the first pieces of direct evidence showing that EPO is able to modulate the dopamine-induced contraction of rat renal arcuate arteries. There are several possible explanations for this finding. The fact that the inhibitory effect of EPO on the dopamine-induced contraction was attenuated by the presence of L-NAME suggests that EPO may induce NO release from these vessels. The observation that the same response was not seen with noradrenaline suggests that, under these conditions, the action of EPO only becomes apparent following activation of a specific receptor, and would argue against the constrictor action of dopamine being mediated via the same receptor subtype as that of noradrenaline, which is most probably the α "A -adrenoceptor (X. C. Wu, N. T. Richards and E. J. Johns, unpublished work). In the rat kidney, the majority of dopamine receptors are located on the vasculature, and only a minority are found on the tubular cells [12] The dopamine-induced relaxation is most probably mediated via stimulation of either D " receptors or β-adrenoceptors on vascular smooth muscle cells [13] . L-NAME caused only a modest attentuation of the relaxation response to dopamine, suggesting that NO was only partially responsible for this relaxation. In the presence of EPO, the degree and magnitude of both acetylcholine-and dopamine-induced relaxation were not altered, which is compatible with the view that, under these circumstances, EPO does not recruit NO release from these vessels.
The other main finding from the present study is that EPO was able to induce NO release from HUVEC, and this effect was not due to a proliferative action of the hormone. Interestingly, this action of EPO took some time to develop, in that only the highest concentration was able to induce NO production after 1 h. However, incubation with lower concentrations of EPO for longer periods (8-24 h) also raised NO production. The mechanism whereby EPO exerts its action on HUVEC is probably different from that by which it affects the dopamine-mediated response : one on endothelial cells, and the other on vascular smooth muscle cells. This direct action of EPO results in stimulation of NO production from HUVEC in culture ; importantly, the effective concentration of EPO was within the range obtained therapeutically in patients treated with EPO, and this would be consistent with the elevated levels of plasma cGMP observed in patients following EPO therapy [5] . The mechanism for this action of EPO on the NO pathway remains to be determined, although one possibility could be a secondary phenomenon via EPOstimulated endothelin-1 release [14, 15] , as endothelin-1 is known to stimulate NO release via ET-B receptors [16] .
The kidney is the major organ of EPO production in adults [17] , and tissue oxygen tension is the major stimulus for EPO generation [18] . It is possible that the effect of EPO on the renal vasculature is part of a feedback mechanism involved in the regulation of EPO generation. Hypoxia will induce the production of EPO ; therefore the local concentration will increase, resulting in NO release, which would in turn decrease renal vascular tone and increase the local tissue blood flow. Therefore the tissue oxygen tension would increase, and EPO production would subsequently be reduced.
It is difficult to reconcile the findings of the present study with the widely reported EPO-induced hypertension. This may simply reflect an inappropriate comparison of acute and chronic experimental studies. However, another possibility may be that overproduction of NO could combine with the superoxide anion (O # − d) to generate the peroxynitrite anion (ONOO − ) [19] , a well known vasoconstrictor.
In conclusion, we have demonstrated that EPO may modulate changes in vascular tone mediated by dopamine and other agonists in rat renal arcuate arteries, probably via the production of NO. Further studies are required to confirm these findings, and to elucidate the physiological role(s) of this mechanism.
